Chimeric Opsin GPCR for Retinal Ganglion Cell Vision Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for retinal neurodegenerative diseases, such as retinitis pigmentosa and age-related macular degeneration, fail to effectively restore vision due to irreversible photoreceptor cell degeneration, with existing strategies like gene editing and expressing photoreceptive proteins in other retinal neurons showing limited efficacy.
Innovation Solution
Expression of a GPCR chimeric opsin, formed by replacing domains of native opsins with mGluR4 domains, in retinal ganglion cells using AAV delivery, allowing these cells to sense light and integrate visual signals through the optic nerve.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If photoreceptive proteins are expressed in other retinal neurons, then vision restoration is achieved, but immune rejection occurs and efficacy is limited
Solution Approach 1:
The patent merges the light-sensing domain of native opsin with the intracellular signaling domains of mGluR4 to create a chimeric protein. This combination allows the chimeric opsin to utilize the endogenous mGluR4 signaling pathway in retinal ganglion cells, thereby restoring vision while avoiding immune rejection since the signaling components are endogenous rather than exogenous
Solution Approach 2:
The chimeric opsin is designed to harness the cell's own endogenous mGluR4 signaling machinery rather than requiring external signaling components. By doing so, the system uses the target cell's intrinsic pathways to transmit visual signals, eliminating the need for additional exogenous proteins that would trigger immune responses
2Adaptability or versatility
If native opsin domains are replaced with mGluR4 domains, then signaling compatibility with retinal ganglion cells is improved, but protein structure complexity increases
Solution Approach 1:
The chimeric opsin is constructed by segmenting the mGluR4 protein into specific functional domains (intracellular loops and C-terminal region) and combining them with the native opsin structure. This segmentation allows only the necessary signaling domains to be transferred, maintaining the light-sensing function of the native opsin while adding compatibility with retinal ganglion cell signaling pathways
Solution Approach 2:
The patent applies local quality by replacing only specific domains of the native opsin (intracellular loops and C-terminal region) with corresponding mGluR4 domains, rather than replacing the entire protein. This localized modification preserves the essential light-sensing properties of the native opsin while conferring signaling compatibility with retinal ganglion cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The GPCR chimeric opsin restores partial vision in blind mice by activating the endogenous signaling pathway of retinal ganglion cells, offering a promising therapeutic strategy with low immune rejection and wide distribution.
Implementation Method 1
GPCRs are an important superfamily of membrane proteins... Extracellular chemical substances act as signaling molecules, i.e., ligands, which bind to GPCRs to mediate downstream intracellular signal transduction
Data Source
Figure 1A~1C
Figure 2~3C
Figure 4
AI summary
Provided are a chimeric opsin GPCR protein for treating retinal neurodegeneration diseases, the chimeric opsin GPCR protein comprising a recombinant opsin formed by replacing a corresponding domain of a natural opsin with at least one domain derived from mGluR4; a nucleic acid molecule and vector encoding the chimeric opsin; a transgenic cell comprising the chimeric opsin, the nucleic acid molecule or the vector; and the use thereof.